- News Releases
Listening to patients is what medical teams at Mayo Clinic do each day. To honor Mayo's 150th Anniversary, StoryCorps was asked to listen to and record several ...
JACKSONVILLE, Flórida — Todos os pacientes com hepatite C, submetidos a transplante de fígado devem se submeter a um tratamento antiviral, antes que seus novos fígados sejam também infectados e fiquem gravemente danificados. O tratamento padrão atual contra Hepatite C pode demorar cerca de um ano, além de ser potencialmente tóxico e poder levar à rejeição do órgão. Agora, no Encontro da Associação Americana para o Estudo das DoeDnças do Fígado (The Liver Meeting® 2014), em Boston, pesquisadores de Clínica Mayo relataram que o uso de dois novos medicamentos orais, depois do transplante, é seguro e benéfico, requerendo apenas 12 semanas de tratamento.
PHOENIX—Mayo Clinic in Arizona, in collaboration with Phoenix Children’s Hospital, has begun treating pediatric patients with complex cancers, using a course of outpatient radiation therapy administered on Mayo’s Phoenix campus. Phoenix Children’s Hospital refers pediatric patients to Mayo Clinic for radiation therapy who are experiencing brain tumors, leukemia, Wilms’ tumor, neuroblastomas, sarcomas and some solid tumors, according to Carol Davis, the Ambulatory Business Operations manager for Phoenix Children’s Center for Cancer and Blood Disorders. Children who are hospitalized at Phoenix Children’s Hospital are transported to Mayo via ambulance, while others come with their parents for the outpatient treatment. Mayo and Phoenix Children’s Hospital have collaborated for a number of years on clinical programs, including pediatric bone marrow transplants and pediatric liver transplants. Radiation Oncology is yet another such collaboration, which maximizes the expertise of both Valley institutions. MEDIA CONTACTS: Lynn Closway, Mayo Clinic, 480-301-4337, Closway.firstname.lastname@example.org Stacy Dillier, Phoenix Children’s Hospital, 602-933-0824, Sdillier@phoenixchildrens.com
http://youtu.be/cTjpk2XwSNc JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection. Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment. “This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida. Journalists: Soundbites with Dr. Pungpapong are available in the downloads. MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: email@example.com